# Endostar Durative Transfusion Combined With Chemotherapy in the Treatment of Advanced Lung Adenocarcinoma

> **NCT02804646** · PHASE4 · UNKNOWN · sponsor: **Anhui Provincial Hospital** · enrollment: 100 (estimated)

## Conditions studied

- Adenocarcinoma of Lung

## Interventions

- **DRUG:** recombinant human endostatin
- **DRUG:** pemetrexed plus cisplatin or carboplatin

## Key facts

- **NCT ID:** NCT02804646
- **Lead sponsor:** Anhui Provincial Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-06
- **Primary completion:** 2017-12
- **Final completion:** 2018-12
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2016-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02804646

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02804646, "Endostar Durative Transfusion Combined With Chemotherapy in the Treatment of Advanced Lung Adenocarcinoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02804646. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*